Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: jopawa who wrote (2220)	8/25/1998 12:06:00 AM
From: jackie	Respond to of 4676

jopawa, This is the info on their website: Remicade (Not currently available for marketing) Centocor has developed Remicade, formerly referred to as Avakine, a chimeric monoclonal antibody that binds to tumor necrosis factor alpha, which is believed to be critical to the human body's reaction to inflammation. Remicade is targeted primarily for the treatment of inflammatory bowel diseases such as Crohn's disease and for rheumatioid arthritis. Centocor completed a Phase III trial in 1997 for moderate-to-severe Crohn's disease, including fistulae, a severe complication of the disease. The company filed a Biologic License Application (BLA) with the FDA on December 30, 1997 for this indication and has received priority review status. Centocor will begin a Phase III trial in the first half of 1998 for the chronic treatment of moderate-to-severe Crohn's patients. The company estimates that there are approximately 250,000 Crohn's patients in the U.S. alone who eventually may benefit from treatment with Remicade. Centocor is currently conducting a Phase III rheumatoid arthritis trial with Remicade. According to recent estimates, in the U.S. and Western Europe there are approximately 1.2 million moderate-to-severe rheumatoid arthritis patients. Centocor estimates up to one-third of these patients may be candidates for treatment with Remicade. Hope that helps Jack